Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN5502
- Development stage
- Preclinical
- Lead developer
- Rui Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KN5502 is a chimeric antigen receptor (CAR)-engineered natural killer (NK) cell therapy being developed by Rui Therapeutics (Shenzhen Enrui Kainuo Biotechnology Co., Ltd.). The therapy is designed to leverage the innate cytotoxic potential of NK cells, enhanced by the specificity of a chimeric antigen receptor to target and eliminate specific cells. As of early 2024, KN5502 is in the early preclinical research and development stage, with its specific molecular target and therapeutic indication currently undisclosed by the developer.
Beyond the preview
Go deeper on KN5502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN5502.